The Effect of a Mediterranean Intermittent Fasting Diet Compared to Weight-reducing Medication on Liver Fibrosis in People With Type 2 Diabetes and Overweight (MEDFAST-study)

Carmen Dietvorst

Status and phase: Enrolling; Phase 4

Conditions: Overweight or Obesity; Liver Steatoses; MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Hepatic Fibrosis; Liver Fibrosis; MASLD; Hepatic Steatosis; Diabetes Mellitus, Type 2

Treatments: Drug: Mysimba; Other: early time restricted Mediterranean diet

Study type: Interventional

Funder types: Other

Identifiers

NCT06845345

2024-519774-40-00 (EU Trial (CTIS) Number)

Details and patient eligibility

About

In the Netherlands, there are many people with type 2 diabetes. More than half of these people also have fatty liver. This is a build-up of fat in the liver (steatosis) and can lead to long-term scarring (fibrosis) and even death of the liver. Losing weight can help reduce this. Losing weight can be done with medication such as Mysimba®, which is often prescribed to people with type 2 diabetes, but losing weight can also be done with diet. In this study, the investigators want to combine a Mediterranean diet (with lots of vegetables, fruits, whole grain products, nuts and olive oil) with intermittent fasting. In addition participants are not allowed to eat after the evening meal. The investigators will compare this with a group of participants receiving Mysimba®, to see if a diet with intermittent fasting might be better for reducing liver steatosis and fibrosis in people with type 2 diabetes.

Enrollment: 70 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes
• Moderate to severe liver fibrosis (LSM >8.0 kPa and <13.6 kPa)
• BMI > 27 kg/m2
• Aged 18-75 years
• Written informed consent

Exclusion criteria

• An insufficient comprehension of the Dutch language (spoken and written)
• Female who is pregnant, breast-feeding or intends to become pregnant
• Participants with an established diagnosis of liver pathology like, but not limited to: Hepatitis B, Hepatitis C, Autoimmune hepatitis, Wilson's disease, Hemochromatosis, Primary biliary cholangitis, Primary sclerosing cholangitis, Alcoholic liver disease
• History of liver transplant, or current placement on a liver transplant list
• History of cirrhosis and/or hepatic decompensation, including ascites, hepatic encephalopathy or variceal bleeding
• Participants with active HIV infection and/or treatment
• Participants with diagnosed malignancies with or without active treatment
• Participants with history or pre-existing renal disease (eGFR <30 mL/min/1.73 m2)
• Participants with corticosteroid induced diabetes (while still using corticosteroids)
• Participants using GLP-1 agonists for less than 3 months or not yet on a stable dose
• Participants using MAO-inhibitors, opioids and/or methadone (due to contraindication)
• Known or suspected excessive alcohol consumption (>21 drinks/week for males or >14 drinks/week for females. One drink is equivalent to 10 grams of alcohol)
• Previous or planned (during the trial period) obesity treatment with surgery. However, previous interventions that, due to reversal or removal, do not have any influence on the patient's weight, in the opinion of the investigator, are allowed.
• Participants with a history or evidence of any other clinically significant condition or planned or expected procedure that in the opinion of the investigator, may compromise the patient's safety or ability to complete the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

70 participants in 2 patient groups

Dietary arm

Active Comparator group

Description:

Calorie restricted Mediterranean diet, with an eating window between 8AM till 6PM (early time-restricted eating)

Treatment:

Other: early time restricted Mediterranean diet

Pharmacological arm

Active Comparator group

Description:

32 mg/360 mg naltrexone/bupropion (Mysimba)

Treatment:

Drug: Mysimba